Quantum Biopharma (NASDAQ:QNTM) Releases Earnings Results, Misses Estimates By $0.49 EPS

Quantum Biopharma (NASDAQ:QNTM) released its quarterly earnings data on Thursday. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.49), Zacks reports.

Quantum Biopharma Stock Down 5.2%

Shares of NASDAQ QNTM traded down $0.20 during mid-day trading on Friday, reaching $3.63. 44,842 shares of the company were exchanged, compared to its average volume of 228,305. The stock has a market capitalization of $13.87 million, a P/E ratio of -0.34 and a beta of 0.32. The company’s 50-day simple moving average is $4.01 and its 200-day simple moving average is $8.91. Quantum Biopharma has a twelve month low of $2.07 and a twelve month high of $38.25.

Analyst Ratings Changes

A number of research firms recently commented on QNTM. Wall Street Zen cut Quantum Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, January 24th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Quantum Biopharma in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Quantum Biopharma stock. Virtu Financial LLC bought a new stake in Quantum Biopharma Ltd. (NASDAQ:QNTM) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 10,406 shares of the company’s stock, valued at approximately $76,000. Virtu Financial LLC owned 0.27% of Quantum Biopharma as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 1.24% of the company’s stock.

About Quantum Biopharma

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.